EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TRIM22-mediated ubiquitin-dependent degradation of FLT3-ITD overcomes TKI resistance in acute myeloid leukemia

Meng Liu, Xiaoqian Wang, Xiaqin He, Xiaoguang Xu, Jing Chen, Juan Liu, Shan Jiang, Sijia Li, Si Wang, Yuanyuan Liu, Jing Feng, Xin Xu und 6 weitere

Life Medicine · 03.06.2026 · 5 (3)

DOI: 10.1093/lifemedi/lnag017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Medicine, online erschienen am 14.05.2026. Verfasst von Meng Liu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Jiao Tong University School of Medicine, Shanghai, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations, found in 25%–30% of acute myeloid leukemia (AML) patients, cause poor prognosis and resistance to FLT3 tyrosine kinase inhibitors (TKIs). We show that APG-115 selectively kills FLT3-ITD cells by activating p53. This critically upregulates TRIM22 (Tripartite motif-containing protein 22), an essential E3 ubiquitin ligase that directly binds FLT3-ITD, promotes its polyubiquitination, and induces its proteasomal degradation. This TRIM22-mediated mechanism offers a novel strategy to overcome intrinsic and acquired TKI resistance. Unlike inhibitors such as AC220, which suppress FLT3 signaling but downregulate p53, APG-115 restores p53 function and induces TRIM22, enabling potent synergy with FLT3 inhibitors. TRIM22 is essential for APG-115’s suppression of leukemia stem cells, inducing cell cycle arrest, myeloid differentiation, and reduced clonogenic potential. The combination of APG-115 and AC220 significantly enhances apoptosis in FLT3-ITD AML models and primary cells, while sparing normal cells. It shows robust efficacy in preclinical xenograft models, reducing tumor burden and extending survival. This work establishes targeting the p53/TRIM22 axis, reliant on TRIM22’s unique activity against FLT3-ITD, as a highly promising therapeutic approach for FLT3-ITD AML, including resistant disease.

Schlagwörter

Stichwörter der Autor:innen

APG-115FLT3-ITDTRIM22acquired resistanceubiquitin

Autor:innen und Institutionen

  • Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
  • Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
  • Department of Blood Transfusion, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
  • Hongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of…

Förderung

  • Shanghai Jiao Tong University School of Medicine, Shanghai, China

Zitieren

APA

Liu, M., Wang, X., He, X., Xu, X., Chen, J., Liu, J., Jiang, S., Li, S., Wang, S., Liu, Y., Feng, J., Xu, X., Luo, M., Li, Z., Zhang, Y., Wu, Y., Hu, J., & Wang, X. (2026). TRIM22-mediated ubiquitin-dependent degradation of FLT3-ITD overcomes TKI resistance in acute myeloid leukemia. Life Medicine, 5(3). https://doi.org/10.1093/lifemedi/lnag017

Vancouver

Liu M, Wang X, He X, Xu X, Chen J, Liu J, et al. TRIM22-mediated ubiquitin-dependent degradation of FLT3-ITD overcomes TKI resistance in acute myeloid leukemia. Life Medicine. 2026;5(3). doi:10.1093/lifemedi/lnag017

BibTeX
@article{Liu2026,
  author = {Liu, Meng and Wang, Xiaoqian and He, Xiaqin and Xu, Xiaoguang and Chen, Jing and Liu, Juan and Jiang, Shan and Li, Sijia and Wang, Si and Liu, Yuanyuan and Feng, Jing and Xu, Xin and Luo, Miaoyin and Li, Zhiyi and Zhang, Yining and Wu, Yingli and Hu, Jian and Wang, Xiaoqin},
  title = {TRIM22-mediated ubiquitin-dependent degradation of FLT3-ITD overcomes TKI resistance in acute myeloid leukemia},
  journal = {Life Medicine},
  year = {2026},
  volume = {5},
  number = {3},
  doi = {10.1093/lifemedi/lnag017}
}
Kostenlos starten →